Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Gilead’s Major Challenge Is Sustainable Model For Remdesivir

With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Bayer Adds Up COVID-19 Pluses and Minuses In Q1

Bayer has beaten analyst forecasts for the first quarter but says the uncertainties brought about by the coronavirus pandemic prevent it from issuing financial guidance for the full year.

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Datamonitor Healthcare's Top Research Reports

Medtech Insight: 世界の医療機器・医療技術の最新情報

MTI Top 100: Leading Medtechs See Steady Organic Growth In A Market On The Cusp Of Change

The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.